A large-scale retrospective study in China explores risk factors for disease severity in plaque psoriasis

Severe psoriasis has a long course and poor outcome, and it has long been a problem for patients. Understanding the independent risk factors that contribute to patients with severe psoriasis is critical for the development of effective treatment strategies. This large, multicenter study recruited 2,109 plaque psoriasis patients from 12 hospitals across China (October 31, 2019 - May 31, 2022). The logistic regression model underwent internal validation and external validation using two independent cohorts over future time periods (June 1, 2022 - January 31, 2023). The discriminative power of our model was substantiated by a C-index of 0.863 (95% CI: 0.848-0.879) in internal validation, further affirmed through 1,000 bootstrap validation (C-index: 0.860, 95% CI: 0.836-0.885) and external validation cohorts, where the C-index reached up to 0.910 (95% CI: 0.868-0.953) and 0.951 (95% CI: 0.924-0.977) in 2 external validation cohorts. To enhance accessibility for clinicians, the model has been made available as a dynamic nomogram and QR code. Our study identified 10 risk factors (the "DELPHI" consensus dichotomy, the DLQI index, the extent of skin involvement as measured by body surface area, the age of the patient at the time of clinical visit, sex, body weight in kilograms, career, the presence of scalp involvement, facial involvement, and arthropathy) for the overall severity of psoriasis (PASI ≥ 10). "Nomogram-10" provides clinicians with a practical tool to develop personalized intervention strategies based on an individual's risk profile.Trial registration: Chinese Clinical Trial Registry: ChiCTR1900024852.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2024-10-28
DOI
https://doi.org/10.1038/s41598-024-73408-6
Citations
1
Primary Topic
Psoriasis: Treatment and Pathogenesis
Type
article
Field-Weighted Citation Impact
0.24
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A large-scale retrospective study in China explores risk factors for disease severity in plaque psoriasis

Huiwei Wang, Xiangtian Liu, Suchun Hou, Yu Chen et al.
1 citations
Scientific Reports
Psoriasis: Treatment and Pathogenesis
0.24
article

A large-scale retrospective study in China explores risk factors for disease severity in plaque psoriasis

Huiwei Wang, Xiangtian Liu, Suchun Hou, Yu Chen, Yuling Shi, Hongzhong Jin, Jialin Lin, Fuqiu Li, Youkun Lin, Jun Gu, Qing Guo, Wei Li, Lin Dang, Gang Wang, Jialiang Shi, Xiaojing Kang, Bin Yang, Mingjun Lei
article en
1 citations

Abstract

Severe psoriasis has a long course and poor outcome, and it has long been a problem for patients. Understanding the independent risk factors that contribute to patients with severe psoriasis is critical for the development of effective treatment strategies. This large, multicenter study recruited 2,109 plaque psoriasis patients from 12 hospitals across China (October 31, 2019 - May 31, 2022). The logistic regression model underwent internal validation and external validation using two independent cohorts over future time periods (June 1, 2022 - January 31, 2023). The discriminative power of our model was substantiated by a C-index of 0.863 (95% CI: 0.848-0.879) in internal validation, further affirmed through 1,000 bootstrap validation (C-index: 0.860, 95% CI: 0.836-0.885) and external validation cohorts, where the C-index reached up to 0.910 (95% CI: 0.868-0.953) and 0.951 (95% CI: 0.924-0.977) in 2 external validation cohorts. To enhance accessibility for clinicians, the model has been made available as a dynamic nomogram and QR code. Our study identified 10 risk factors (the "DELPHI" consensus dichotomy, the DLQI index, the extent of skin involvement as measured by body surface area, the age of the patient at the time of clinical visit, sex, body weight in kilograms, career, the presence of scalp involvement, facial involvement, and arthropathy) for the overall severity of psoriasis (PASI ≥ 10). "Nomogram-10" provides clinicians with a practical tool to develop personalized intervention strategies based on an individual's risk profile.Trial registration: Chinese Clinical Trial Registry: ChiCTR1900024852.

Scientific ReportsVol. 14(1)
Tongji University (CN), Guangxi Medical University (CN), Shenzhen University (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Sichuan University (CN), Peking Union Medical College Hospital (CN), Longgang Central Hospital (CN), Shenzhen Sixth People's Hospital (CN), People's Hospital of Xinjiang Uygur Autonomous Region (CN), Hebei University of Chinese Medicine (CN), First Affiliated Hospital of GuangXi Medical University (CN), Shanghai Tenth People's Hospital (CN), Affiliated Hospital of Hebei University (CN), University of Hong Kong - Shenzhen Hospital (CN), First Bethune Hospital of Jilin University (CN), Shanghai Skin Disease Hospital (CN), Xijing Hospital (CN), Huazhong University of Science and Technology (CN), Southern Medical University (CN), University of Hong Kong (HK), Air Force Medical University (CN)
Good health and well-being
Openalex Percentile: Top 41%
Psoriasis: Treatment and Pathogenesis
0.24
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.